From strain to shelf: probiotics, prebiotics, postbiotics, enzymes, and precision delivery—engineered for potency, stability, and scientific credibility.
The Global Benchmark for Gut Health Supplement CDMOs
Elise Biopharma stands at the frontier of microbiome manufacturing—where the complexity of living organisms meets the rigor of pharmaceutical engineering. As a Gut Health Supplement CDMO, we don’t just make products that survive the gastrointestinal journey—we make systems that thrive within it. Every capsule, gummy, or sachet is built from controlled biological principles, optimized by real bioprocess data, and validated by reproducible results.
Gut health today is not a single market—it is a revolution in human biology. The next decade will see functional supplements evolve into personalized microbial ecosystems, blending probiotics, postbiotics, enzymes, and bioactive prebiotic fibers. This transformation demands CDMOs with dual fluency: the scientific precision of therapeutic biologics and the efficiency of nutraceutical manufacturing. Elise Biopharma uniquely bridges both worlds.
Probiotics, Prebiotics, Postbiotics, Enzymes…
Our clients—from global nutrition brands to cutting-edge biotech startups—choose us because we deliver GMP-grade microbiome manufacturing with scalability, validated stability, and market-ready compliance. If your ambition is to build a differentiated, evidence-backed, consumer-trusted gut health brand, Elise Biopharma is the Gut Health Supplement CDMO partner capable of taking you from microbial strain to global shelf.
Why Gut Health Supplements Require a CDMO Like Elise Biopharma
Traditional supplement manufacturing treats probiotics like commodities. But in truth, these are biological entities that respond to their environments—oxygen, moisture, excipients, and time all dictate their survival. As the world’s most advanced Gut Health Supplement CDMO, Elise Biopharma approaches every project as a living system to be engineered, not a powder to be packed.
Our process control begins at the molecular level. Every strain, prebiotic, and excipient is characterized through spectroscopy, metabolomics, and moisture-activity mapping. Each formulation is simulated under gastrointestinal pH gradients, oxygen exposure, and long-term shelf conditions to ensure CFU accuracy at expiry—not just at batch release.
The result: products that perform in vitro, in vivo, and in market.
Purpose-Built for Gut Health Brands
Gut health is an ecosystem—alive, reactive, and interconnected. A meaningful product must engage the entire chain:
- Microbial metabolism (via probiotics and synbiotics)
- Gut barrier reinforcement (via postbiotics and peptides)
- Digestive efficiency (via enzymatic blends)
- Inflammation modulation (via targeted bioactives and antioxidants)
At Elise Biopharma, our Gut Health Supplement CDMO platform integrates these domains through one core philosophy: formulation is a biological equation. We calculate not only CFU counts and enzyme activity but how those systems co-exist, synergize, and survive.
Our approach blends:
- Biopharma-grade process discipline — aseptic handling, oxygen control, validated bioreactors.
- Nutraceutical scalability — optimized cost of goods, fast turnaround, and food-safe compliance.
- Predictive modeling — data-driven simulations that anticipate viability losses across time and environment.
When the product leaves our facility, it’s not just stable—it’s validated by physics and biology.
What we make (and make work)
Product types
- Probiotics (lactic acid bacteria, bifidobacteria, bacilli, S. boulardii)
- Paraprobiotics & Postbiotics (heat-treated cells; cell wall fractions; metabolites such as SCFAs/peptides)
- Synbiotics (strain + selective prebiotic substrate)
- Prebiotics (inulin, FOS/GOS, XOS, RS2/RS3, arabinogalactans, polyphenol fibers)
- Digestive & systemic enzymes (lactase, proteases, lipases; specialty blends)
- Adjacents (glutamine, zinc-carnosine, botanicals with gut affinity, electrolytes)
Formats & delivery
- HPMC/DRcaps®/enteric capsules; microbeadlets; dual-phase capsules
- Stick packs/sachets, jar powders, shots, ready-to-mix
- Gummies with microencapsulated actives
- Coatings & encapsulation: alginate, lipid/polymer, pH-triggered films
- Targeting: acid protection → intestinal release; moisture/oxygen control; oxygen-scavenger systems for anaerobes
Our integrated platform
1) Strain & ingredient development
- Media design and scale-up for Lactobacillus, Bifidobacterium, Bacillus, S. boulardii; oxygen-sensitive/anaerobic workflows
- Postbiotic process design (ferment, inactivate, fractionate, standardize actives)
- Enzyme expression or sourcing, activity standardization (FCC/USP methods)
- Synbiotic pairing via in-vitro selectivity screens (which prebiotic feeds your strain, not the generic average)
2) Upstream & downstream bioprocess
- Fermentation: 1 L feasibility → 2,000–5,000 L commercial; aerobic/anaerobic control, redox & pH strategy
- Harvest & polish: continuous centrifugation, microfiltration/TFF, buffer exchange
- Stabilization: lyophilization; spray-dry with glass-forming excipients; vacuum foam drying for fragile strains
- Standardization: CFU/activity titering, carrier blending, moisture-activity tuning (aw)
3) Formulation engineering
- Microencapsulation to raise simulated gastric survival and room-temp shelf life
- Excipient systems: trehalose, resistant starches, skim-milk analogs, amino-acid glasses, lipids
- Compatibility mapping: enzymes vs. probiotics (protease containment), polyphenols vs. viability, prebiotic hygroscopicity vs. aw
- Sensory optimization for RTM powders and gummies without harming CFUs or enzyme activity
4) Analytical & stability (designed for label truth)
- Potency: plate counts, flow cytometry, viability-qPCR; enzyme activity assays
- Identity & purity: qPCR/NGS strain ID; AMR/toxin gene screens; WGS on request
- Postbiotic release specs: metabolite markers (SCFAs/organic acids/peptides) by LC/GC-MS
- Stability: ICH-style accelerated/long-term, humidity/temperature cycling, packaging challenge studies
- In-vitro performance: simulated saliva/gastric/intestinal fluids; bile tolerance; dissolution for enteric systems
5) Regulatory & claims support
- US GRAS/NDI, EU Novel Food, Canada NHP mapping and dossier drafting support
- Claim substantiation frameworks (structure/function) + human study design guidance with CRO partners
- Retail/market compliance: label accuracy programs; specification files and CoAs ready for audits
6) Manufacturing & packaging
- Food-grade/GMP-aligned suites; allergen-aware flows; segregation for enzymes vs. microbes
- High-shear and low-shear blending; anti-segregation design for multi-strain blends
- Capsule fill, stick-pack/sachet, jar lines; gummy compounding with heat/aw constraints
- Packaging selection by water vapor transmission rate (WVTR) & oxygen ingress; integrated desiccant/oxygen scavengers
Build it like a medicine, price it like a supplement
We use a streamlined QbD spine so consumer products inherit biopharma reliability:
- QTPP (Target Product Profile): dose form, CFU/activity at expiry, storage, claims
- CQAs (Critical Quality Attributes): viability/activity curves, moisture, permeability, identity & purity, sensory
- CPPs (Critical Process Parameters): feed rates, harvest/cryoprotectant windows, drying profiles, encapsulation conditions
- Control strategy: PAT where useful (pH/redox/DO; in-process CFU/activity read-outs), release analytics tied to claims
Differentiators You Can Feel on the Shelf
Elise Biopharma builds gut health systems from the inside out—formulation first, molecule second. Every differentiator below rests on measurable process control, not marketing copy.
Anaerobe-Capable Handling for Oxygen-Sensitive Strains
Most “probiotic facilities” claim anaerobic capacity; few actually hold redox potential below –150 mV during harvest and blending.
We operate modular nitrogen-blanketed suites with inline dissolved oxygen sensors, oxygen-scrubbed air knives, and argon-purged blending drums.
- Dynamic DO mapping: Continuous in-situ probes quantify O₂ ingress per unit time; data feed a predictive decay model for CFU loss.
- Anaerobic fill-finish: Single-use isolators with gas-exchange rates < 0.1 ppm O₂ maintain viability for Faecalibacterium, Bifidobacterium adolescentis, and similar fastidious strains.
Postbiotics at Parity with Probiotics
“Heat-killed” is marketing shorthand; our postbiotics are quantified bioactive matrices.
- Metabolite fingerprinting: GC-MS and LC-MS/MS quantitation of lactate, butyrate, SCFAs, and peptide fragments establishes a release profile and pharmacodynamic surrogate.
- Functional reference assays: Tight-junction reinforcement (Caco-2 TEER), cytokine modulation, and ROS suppression assays ensure each lot meets biological potency specs.
- Process analytics: Controlled thermal or pressure inactivation (< 3 log CFU residual) under defined protein-carbonyl thresholds prevents denaturation beyond activity loss.
Synbiotic Rational Design
Instead of defaulting to inulin or FOS, we identify strain-specific carbon preference through Biolog AN MicroPlate phenotyping and RNA-seq metabolic flux analysis.
- Pairing algorithm: Machine-learning model correlates prebiotic structure (DP, branching index) with growth kinetics and metabolite yield for target strains.
- Co-fermentation screening: Parallel fed-batch trials measure synergy via short-chain-fatty-acid output and CFU persistence.
- Outcome: Synbiotics tuned for selectivity (fueling your strain, not competitors in the gut).
Enzyme–Microbe Co-Formulations That Don’t Self-Sabotage
Enzymes digest food—and sometimes your CFUs. We prevent this molecular cannibalism.
- Phase-segregated encapsulation: Dual-chamber capsules or lipid microcaps separate protease activity until pH > 6.
- Kinetic modeling: Michaelis–Menten constants measured at formulation pH to calculate safe enzyme overage.
- Activity retention: Controlled water activity (0.20–0.30 aw) maintains both enzyme kinetics and probiotic dormancy.
Delivery Proof, Not Promises
Every product includes a Simulated GI Transit File—a dataset, not a tagline.
- Gastric-to-intestinal survival mapping: Using USP <711> dissolution apparatus with SGF pH 1.2 → SIF pH 6.8 transition, we quantify log-survival curves per capsule.
- Enteric validation: FTIR & DSC analyses confirm coating integrity after 2 h acid exposure.
- Release kinetics modeling: Weibull and Korsmeyer–Peppas fits describe probiotic liberation rate through the small intestine.
Label Accuracy & Potency to Expiry
We back every CFU and enzyme unit on-label with predictive stability modeling.
- Overage simulation: Arrhenius kinetics (Ea ≈ 45 kJ mol⁻¹ typical) predict viability loss under 25 °C/60 % RH; overage is precisely dosed to maintain ≥ 100 % label claim at 24 months.
- Batch-specific QR traceability: Each lot linked to real-time stability dashboard; deviations trigger proactive replenishment before market expiry.
Example Build Paths — Technical Archetypes
1. Probiotic-Forward Capsule
L. rhamnosus GG + L. plantarum 299v → microencapsulation via fluidized-bed coating (alginate + Eudragit L100-55) → DRcaps® enteric → validated 24-month CFU retention at 25 °C.
Data package: aw 0.18, O₂ < 0.2 ppm, log survival –0.2 after 6 months accelerated.
2. Synbiotic Powder Stick
B. longum BB536 + resistant starch type 3 + trehalose matrix → fluid-bed agglomeration with 3 % lipid coating → ≤ 0.25 aw under 70 % RH climate test → no clumping, 95 % CFU retention 12 mo @ 40 °C.
3. Postbiotic Gummy
Fermentate standardized to lactate:acetate = 3:1 ± 0.2; peptide marker < 2 kDa ≥ 80 µg/g.
Included in gelatin system at 85 °C; potency verified post-cook via metabolomics.
4. Enzyme + Probiotic Dual-Phase Capsule
Protease (500 HUT) in delayed-release shell; B. coagulans spore core (10⁹ CFU).
Moisture barrier: lipid interphase 15 µm ± 2 µm.
No cross-degradation at 40 °C / 75 % RH 90 days.
Quality, Safety & Certifications — Deeper Compliance Backbone
- GMP-aligned nutraceutical suites built to ISO 22000 & 13485 hybrid; HEPA H14 filtration with viable particle counts logged to LIMS.
- HACCP + HARPC integrated plan linking Critical Control Points (CCPs) directly to electronic batch records.
- Allergen & cross-contact mapping: CFD airflow modeling between blending rooms; validated 3-log allergen reduction clean-down.
- AMR/toxin gene analytics: Shotgun WGS screened against CARD & VFDB; negative certification appended to CoA.
- Vendor qualification: Non-GMO, vegan, halal, and kosher documentation; elemental impurity testing per USP <232>.
- Audit readiness: Full documentation trail – IQ/OQ/PQ, preventive maintenance, calibration, stability, and deviation logs accessible through secure portal.
Engagement Model & Timelines — Engineered for Gut Health CDMO Precision
Elise Biopharma’s engagement model reflects the discipline of pharmaceutical development fused with the agility of nutraceutical scale. As the world’s most advanced Gut Health CDMO, we architect every project around data, reproducibility, and regulatory foresight—transforming biological complexity into manufacturing predictability. Our phased framework ensures that every gut health product moves from discovery to global launch under validated, evidence-driven control.
Phase 1: Discovery & Technical Blueprint
Every Gut Health CDMO partnership begins with clarity of purpose. We start by dissecting the scientific and commercial intent of your formulation—its biological mechanism, desired delivery route, and market positioning.
- Defining the biological objective: mapping strain function (immunomodulatory, digestive, metabolic) to claim architecture.
- Regulatory and pathway strategy: food supplement vs. NHP vs. novel food vs. functional food, aligned with FDA, EFSA, or Health Canada.
- Designing the QTPP (Quality Target Product Profile): dosage form, shelf-life target, CFU retention curve, enzyme activity index.
- Building the CQA matrix: identifying parameters that determine efficacy—viability, pH tolerance, bioactive concentration, sensory integrity.
- Data foundations: predictive analytics for cost-of-goods, packaging compatibility, and cold-chain vs. ambient logistics modeling.
At this stage, the Gut Health CDMO focus is conceptual precision—ensuring your biological idea already functions as a manufacturable product on paper before a single fermentor runs.
Phase 2: Formulation & Process Development
Here the biology meets the bioreactor. Our Gut Health CDMO teams translate concept into tangible data through iterative, small-scale fermentation and formulation cycles.
- Pilot Fermentations: 1–10 L runs to establish oxygen tolerance, redox balance, and nutrient consumption rates.
- GI Simulation: in-vitro gastric and intestinal exposure tests confirm survivability and release timing.
- Stability Mapping: multi-point shelf-life projections across temperature and humidity gradients.
- Sensory & Packaging Integration: ensuring texture, flavor, and delivery form are compatible with microbial activity.
- Tech Transfer Design: every pilot run is digitally logged and converted into a reproducible, scalable protocol.
By the end of this phase, Elise Biopharma’s Gut Health CDMO pipeline transforms theoretical performance into statistical assurance—showing, not claiming, that your probiotic, enzyme, or synbiotic formulation will survive, function, and satisfy.
Phase 3: Scale-Up & Validation
Scaling living systems requires mastery of kinetics, oxygen control, and downstream recovery. Our Gut Health CDMO infrastructure supports fermentation volumes from 1 L benchtop to 5,000 L commercial bioreactors—seamlessly translating lab conditions into industrial reliability.
- Engineering Batches: reproducibility testing at target volumes using oxygen, pH, and agitation control identical to commercial parameters.
- CPP Mapping: every critical process parameter—feed rate, temperature ramp, gas composition—is logged and statistically modeled (Cpk ≥ 1.33).
- Downstream Optimization: real-time viability tracking through centrifugation, filtration, drying, and encapsulation.
- Validation Protocols: IQ/OQ/PQ documentation ensures your process is auditable and compliant with global GMP standards.
No other Gut Health CDMO offers such granular control over biological yield, process efficiency, and scale continuity. You receive not just product, but process ownership.
Phase 4: Commercial Launch & Lifecycle Management
When your gut health formulation is ready for the world, Elise Biopharma ensures it stays ready—batch after batch, year after year.
- Concurrent Manufacturing & QC: overlapping production and release testing shorten lead times while maintaining regulatory rigor.
- Shelf-Life Monitoring: continuous CFU and enzyme activity tracking using accelerated and real-time stability models.
- Parallel SKU Development: multi-format variants (capsules, gummies, RTM powders) scaled under shared analytics and identical quality systems.
- Post-Launch Optimization: periodic data reviews refine formulations for longer shelf life, improved sensory appeal, or new claim opportunities.
Every client is integrated into our Gut Health CDMO ecosystem—complete with dashboards for live data access, deviation logs, and predictive restock planning.
FAQs —Gut Health CDMO Insights
1. Can you guarantee CFU potency through expiry?
Yes. Each formulation’s overage is modeled via Arrhenius kinetics corrected for humidity and oxygen ingress. We validate with 12-month accelerated (40 °C/75 % RH) and 24-month real-time stability. Results are tied to statistical confidence intervals (95 %) for regulatory defensibility.
2. Are live probiotic gummies feasible?
Feasible with <200 µm microencapsulation, sub-90 °C cook points, and aw ≤ 0.25. We use emulsified lipid shells and antioxidant systems to preserve viability. For ambient stability, we create postbiotic equivalents benchmarked by GC-MS metabolite retention.
3. Do you handle clinical validation or dossier preparation?
Yes. As a Gut Health CDMO, we coordinate global CRO studies using metagenomic sequencing, qPCR CFU tracking, and validated clinical endpoints. CMC and GRAS/NHP dossiers are compiled in-house to FDA, EFSA, and Health Canada standards.
4. How do you prevent enzymes from degrading probiotics?
Through phase-segregated encapsulation, cross-linked protein barriers, and time-release layering. Moisture activity is maintained ≤ 0.3 so proteases stay latent until small-intestinal pH triggers release.
5. How do you stabilize anaerobic strains like Faecalibacterium prausnitzii?
We use argon-purged fermentors, inline redox sensors (< –150 mV), and gas-exchange isolators. Downstream, oxygen-scrubbed blending and low-O₂ barrier packaging (< 0.1 ppm ingress) sustain viability through shelf life.
6. What differentiates your postbiotics from “heat-killed” products?
Our postbiotics are analyte-anchored matrices with quantified SCFAs, peptides, and organic acids measured by LC–MS/MS. Functional activity (tight-junction TEER, cytokine modulation) defines potency—not residual CFUs.
7. How do you design strain-specific synbiotics?
We map carbon-utilization phenotypes with Biolog AN plates and RNA-seq, then feed the data into machine-learning flux models that pair prebiotics by metabolic fit—ensuring selectivity, not random FOS pairing.
8. Can you combine probiotics with botanicals or polyphenols?
Yes, but only after redox-compatibility screening. Polyphenol antioxidants can quench microbial respiration; we mitigate via microencapsulation and pH-specific release to prevent cross-reactivity.
9. How is shelf life predicted for ambient products?
We employ predictive degradation models incorporating temperature, relative humidity, and oxygen ingress rates. Each product receives a CFU half-life equation and confidence-based expiry projection.
10. Do you perform genetic identity testing on strains?
Every master cell bank undergoes whole-genome sequencing, AMR gene screening via CARD, and plasmid stability testing through ≥ 10 passages. qPCR fingerprinting confirms strain authenticity per lot.
11. How do you validate capsule enteric protection?
We test using USP <711> dissolution and pH-shift apparatus simulating SGF → SIF transitions. FTIR confirms intact polymer cross-linking after two hours in acid before intestinal release.
12. What water-activity and humidity limits apply to powders?
For gut-health blends we hold aw ≤ 0.25 at 25 °C and equilibrium RH ≤ 40 %. Dynamic-sorption analysis defines desorption isotherms, predicting clumping and CFU loss thresholds.
13. Can you make multi-strain blends without competitive inhibition?
Yes. We quantify bacteriocin interactions and co-culture metabolite interference. Formulations are optimized through factorial DoE to ensure balanced growth and neutral pH cross-effects.
14. How are digestibility and bioaccessibility measured?
We simulate digestion via INFOGEST protocols (oral, gastric, intestinal) and track survival and metabolite release with HPLC and plate counts. Data inform encapsulation and excipient selection.
15. Do you manage endotoxin and toxin-gene risk?
Yes. Each lot is tested for endotoxin (LAL < 0.5 EU/mg), toxin gene exclusion (PCR), and hemolytic activity. Only non-pathogenic, GRAS-validated strains enter production.
16. How do you ensure regulatory compliance across regions?
We maintain integrated templates for GRAS (USA), NDI, Novel Food (EU), and NHP (Canada). Our regulatory unit harmonizes dossier content for multi-jurisdictional submissions.
17. What packaging solutions extend shelf life?
High-barrier aluminum laminates, nitrogen flushes, desiccant sachets sized via water-vapor transmission modeling, and oxygen-scavenger inserts. Real-time monitoring confirms internal O₂ < 0.2 %.
18. How do you quantify postbiotic metabolites?
Through untargeted metabolomics (LC-HRMS) followed by targeted quantitation of SCFAs, peptides, and organic acids. Data form each product’s metabolite fingerprint certificate.
19. Do you perform in-vitro microbiome interaction testing?
Yes. Using fecal fermentation models and 16S rRNA sequencing, we evaluate how candidate strains influence native microbiota composition—critical for precision gut-health claims.
20. How does Elise Biopharma differ from other Gut Health CDMOs?
We unite biopharma-grade GMP infrastructure, anaerobic mastery, and omics-driven formulation science. Every capsule is treated as a controllable bioreactor obeying measurable kinetics—proof that manufacturing and biology can finally speak the same language.
Why Elise Biopharma — The Apex of Gut Health CDMOs
Elise Biopharma treats every product like a miniature, closed-loop bioreactor—a living, controllable ecosystem where thermodynamics, mass transfer, and microbial kinetics are engineered to obey you, not chance. Elise is the best Gut Health CDMO —see why below.
Bioprocess rigor that actually moves the needle.
Our upstream and downstream trains are instrumented with AI-assisted PAT (inline redox, DO, Raman/FTIR where appropriate) to keep viability, metabolite profiles, and moisture activity on their rails. We don’t “hope” a strain survives encapsulation—we model its survival curve and prove it under simulated GI and ICH stability.
Scientific differentiation you can cite in a label review.
Where others sell “heat-killed,” we standardize postbiotics by analyte (SCFAs, peptides, organic acids) with LC-MS/MS fingerprints; where others toss FOS at everything, we build precision synbiotics via carbon-flux phenotyping and RNA-seq. Delivery claims aren’t slogans; they’re enteric dissolution plots, survival kinetics, and release models your regulatory team can defend.
Scale without drama—ever.
From 1 L feasibility to 5,000 L commercial, we hold CPPs within control limits (Cpk ≥ 1.33) before validation, so scale-up behaves like copy-paste, not coin-flip. Form factors (capsule, stick, gummy) run under a single analytics spine, which means multi-SKU rollouts without requalification whiplash.
Predictive reliability that eliminates supply-chain surprises.
You get real-time dashboards for CFU decay forecasts, aw drift, oxygen ingress, and packaging WVTR performance. Deviations trigger countermeasures before they become complaints. It’s the difference between “we’ll see” and “we already fixed it.”
Regulatory fluency baked into the process, not stapled on.
GRAS/NDI, Novel Food, and NHP dossiers are assembled from day-one data trails (WGS identity, AMR screens, TEER assays, dissolution, stability kinetics). Audits aren’t a scramble because every lot is dossier-ready.
Outcome guarantees—tied to physics, not wishful thinking.
When Elise sets a label claim, we back it with Arrhenius-based overage models, humidity-corrected decay, and accelerated + real-time confirmation. Your claims hold to expiry because the process was designed around that fact from the first experiment.
R&D that keeps you a version ahead.
Postbiotic metabolome libraries, anaerobe handling that actually holds <0.2 ppm O₂, microencapsulation that survives the oven, and dual-phase enzyme/probiotic architectures—we commercialize what others present at conferences.
In short: Elise Biopharma is not one more vendor in the aisle. Elise Biopharma is the Gut Health CDMO other manufacturers benchmark against—the team that writes the playbook on viabilities that stick, postbiotics that matter, and synbiotics that do more than decorate a label.
If you want gut health products that behave like engineered systems—and win like them—there is one clear partner.
Let’s Engineer the Future!
Your consumers don’t just need “probiotics.” They need engineered ecosystems that work in the real world. Partner with Elise Biopharma—the Gut Health CDMO trusted by innovators who demand scientific proof, scalable precision, and global credibility.
Interested in our Probiotics & Synbiotics services? Click –> Probiotics & Synbiotics
Email our team directly at info@elisebiopharma.com